Mazama Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Mazama Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-22,704	Closed	-$1.03M	–	219
2015 Q4	$1.03M	Buy	+22,704	New	+$1.19M	0.19%	113
2015 Q2	–	Sell	-739	Closed	-$57K	–	319
2015 Q1	$57K	Buy	+739	New	+$42.6K	0.01%	205

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Mazama Capital Management's ONCE Position: Q1 2016 in Review

Mazama Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2016, closing a stake of 22,704 shares — an estimated $1.03M sold.

Mazama Capital Management first reported a position in ONCE in Q1 2015 and held it in 2 quarters. The position peaked at $1.03M in Q4 2015. 105 funds tracked by Wall St. Rank hold ONCE as of Q1 2016.

Mazama Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
Mazama Capital Management sold 22,704 Spark Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $1.03M.
Mazama Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 2 quarters.
Mazama Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $1.03M in Q4 2015.
105 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Mazama Capital Management's 13F filing for Q1 2016.